Brought to you by 
Bayer buys protein engineering firm Direvo for €210mm cash
01 Oct 2008
Executive Summary
Bayer HealthCare is paying €210mm ($300mm) in cash to acquire private bioengineering company Direvo Biotech AG. The transaction excludes Direvo's industrial biotechnology subsidiary, which focuses on enzymes for food and biorefinery markets and was sold separately to financial investors.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer buys protein engineering firm Direvo for €210mm cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice